Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
Status:
Completed
Trial end date:
2013-04-16
Target enrollment:
Participant gender:
Summary
Hyperparathyroidism (HPT) is common in people with a kidney transplant. Patients with HPT
often have high parathyroid hormone (PTH) levels and may have large parathyroid glands in the
neck. Patients with HPT can develop bone disease (osteodystrophy). This bone disease can
cause bone pain, fractures, and poor formation of red blood cells. Other problems from HPT
may include increases in blood levels of calcium (hypercalcemia) and low blood levels of
phosphorus (hypophosphatemia). The high calcium levels may cause calcium to deposit in body
tissues. Calcium deposits can cause arthritis (joint pain and swelling), muscle inflammation,
itching, gangrene (death of soft tissue), heart and lung problems or kidney transplant
dysfunction (worsening of kidney transplant function). The purpose of this study is to
evaluate the effects of cinacalcet (Sensipar/Mimpara) on high calcium levels in the blood in
patients with HPT after a kidney transplant.